Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 elevation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PD-L1 elevation	HER2 Positive Breast Cancer	PD-L1 elevation	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PD-L1 elevation	Non-Hodgkin’s Lymphoma	PD-L1 elevation	Non-Hodgkin’s Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
PD-L1 elevation	Urothelial Cancer	PD-L1 elevation	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
PD-L1 elevation	Non Small Cell Lung Cancer	PD-L1 elevation	Non Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
PD-L1 elevation	Non Small Cell Lung Cancer	PD-L1 elevation	Non Small Cell Lung Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
PD-L1 elevation	Non Small Cell Lung Cancer	PD-L1 elevation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Bladder Cancer	PD-L1 elevation	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Neuroendocrine Tumor	PD-L1 elevation	Neuroendocrine Tumor	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
PD-L1 elevation	Colorectal Cancer	PD-L1 elevation	Colorectal Cancer	durvalumab + tremelimumab Resistant: C3 – Early Trials durvalumab + tremelimumab Resistant : C3	durvalumab + tremelimumab Resistant: C3 – Early Trials durvalumab + tremelimumab Resistant : C3
PD-L1 elevation	Solid Tumor	PD-L1 elevation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Urothelial Cancer	PD-L1 elevation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Small Cell Lung Cancer	PD-L1 elevation	Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Melanoma	PD-L1 elevation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Lung Cancer	PD-L1 elevation	Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 elevation	Non Small Cell Lung Cancer	PD-L1 elevation	Non Small Cell Lung Cancer	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D